http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Fei-meng Zheng ),( Wang-bing Chen ),( Tao Qin ),( Li-na Lv ),( Bi Feng ),( Yan-ling Lu ),( Zuo-quan Li ),( Xiao-chao Wang ),( Li-ju Tao ),( Hong-wen Li ),( Shu-you Li ) 생화학분자생물학회 2019 BMB Reports Vol.52 No.9
Lymphoma is one of the most curable types of cancer. However, drug resistance is the main challenge faced in lymphoma treatment. Peroxisomal acyl-CoA oxidase 1 (ACOX1) is the rate-limiting enzyme in fatty acid β-oxidation. Deregulation of ACOX1 has been linked to peroxisomal disorders and carcinogenesis in the liver. Currently, there is no information about the function of ACOX1 in lymphoma. In this study, we found that upregulation of ACOX1 promoted proliferation in lymphoma cells, while downregulation of ACOX1 inhibited proliferation and induced apoptosis. Additionally, overexpression of ACOX1 increased resistance to doxorubicin, while suppression of ACOX1 expression markedly potentiated doxorubicin-induced apoptosis. Interestingly, downregulation of ACOX1 promoted mitochondrial location of Bad, reduced mitochondrial membrane potential and provoked apoptosis by activating caspase-9 and caspase-3 related apoptotic pathway. Overexpression of ACOX1 alleviated doxorubicin-induced activation of caspase-9 and caspase-3 and decrease of mitochondrial membrane potential. Importantly, downregulation of ACOX1 increased p73, but not p53, expression. p73 expression was critical for apoptosis induction induced by ACOX1 downregulation. Also, overexpression of ACOX1 significantly reduced stability of p73 protein thereby reducing p73 expression. Thus, our study indicated that suppression of ACOX1 could be a novel and effective approach for treatment of lymphoma. [BMB Reports 2019; 52(9): 566-571]
Liu Peng-Cheng,Peng Yi-Lin,Li Jian-Bin,Lv Meng-Na,Yu Shu-Jiao,Wu Rui 대한피부과학회 2024 Annals of Dermatology Vol.36 No.3
Background: A higher incidence of herpes zoster (HZ) was found in people with decreased cell-mediated immunity. However, the relationship between cellular immunity and HZ infec- tion in patients with autoimmune inflammator y rheumatic diseases (AIRD) remains elusive. Objective: To investigate the role of CD4/CD8 ratio in patients with AIRD and HZ. Methods: This case-control study compared AIRD patients with and without HZ. We chose 70 AIRD patients with HZ as the experimental group and 140 AIRD patients without HZ as the control group. The clinical and laborator y findings were assessed in each trial participant. Results: The CD4/CD8 ratio (odds ratio [OR], 0.22; 95% confidence inter val [CI], 0.10–0.49) was independently associated with the occurrence of HZ after adjusting for various confounders. Nonlinear analysis has unveiled a more profound nonlinear relationship between the CD4/CD8 ratio and the occurrence of HZ in patients with AIRD. The OR of HZ increased with a decreasing CD4/CD8 ratio before the turning point of 2. The adjusted regression coefficient was 0.14 (95% CI, 0.05–0.37, p<0.0001) for CD4/CD8 ratio less than 2. Conclusion: The CD4/CD8 ratio was expected to be a ver y promising quantitative biomarker for predicting the risk of developing HZ in patients with AIRD.